Odyssean LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 125,062 shares of the company's stock, valued at approximately $3,217,000. Denali Therapeutics makes up approximately 0.5% of Odyssean LLC's investment portfolio, making the stock its 29th largest position. Odyssean LLC owned 0.08% of Denali Therapeutics at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of DNLI. BlackRock Inc. purchased a new position in Denali Therapeutics in the 2nd quarter valued at approximately $360,759,000. Norges Bank bought a new position in shares of Denali Therapeutics in the fourth quarter worth $84,525,000. ADAR1 Capital Management LLC boosted its holdings in shares of Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock worth $35,932,000 after acquiring an additional 1,819,339 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Denali Therapeutics by 77.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company's stock valued at $63,329,000 after purchasing an additional 1,672,098 shares in the last quarter. Finally, Temasek Holdings Private Ltd grew its position in shares of Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock valued at $115,784,000 after purchasing an additional 1,657,142 shares in the last quarter. Institutional investors own 92.92% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on DNLI shares. Morgan Stanley increased their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Wall Street Zen upgraded Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an "overweight" rating and a $29.00 price target on the stock. Robert W. Baird set a $34.00 price objective on shares of Denali Therapeutics in a research report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.85.
Check Out Our Latest Stock Report on DNLI
Denali Therapeutics Price Performance
Shares of NASDAQ:DNLI opened at $24.93 on Wednesday. The company's fifty day moving average price is $24.55 and its 200-day moving average price is $21.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of -8.78 and a beta of 1.01. Denali Therapeutics Inc. has a one year low of $12.58 and a one year high of $27.30.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same period in the prior year, the company earned ($0.72) earnings per share. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the sale, the insider owned 281,763 shares of the company's stock, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.70% of the stock is owned by insiders.
About Denali Therapeutics
(
Free Report)
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.
Further Reading
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
